Oneomics Inc | Application Preview
Oneomics Inc. is seeking government grants to complete its research and development efforts on a groundbreaking clinical single cell diagnostic test, starting with a laboratory developed test format. The company aims to advance the standard complete blood count (CBC) by introducing the Next Generation CBC (NGC), a single cell genomics technology that provides a detailed analysis of hundreds of distinct immune cell types and states, rather than just a few basic types.
The rationale for funding approval is rooted in the importance of understanding the immune system's complexity for effective disease prevention and treatment. The NGC represents a significant enhancement over traditional CBC tests, enabling healthcare providers to leverage the intricate diversity of blood cells for precision medicine.
Oneomics has no direct competitors in this innovative diagnostic space, presenting a unique opportunity to transform a widely used clinical test. By securing this funding, the company aims to lead the way in personalized health diagnostics for the future.
-
General Information
Business Registration Number: 4811420
Location: MENLO PARK, CA, United States
Length of Operation: 1-5
Number of Employees: 1-10 Employees
Annual Gross Income: Less than $100k
Annual Gross Expense: Less than $100k
Open to Loans: YES
-
Funding Usage
Finish research and development
-
Business Plan
Introduce the first clinical single cell diagnostic, initially as a laboratory developed test. We all have a unique immune system that helps to protect us from disease. Doctors have used this information ever since the first scientists looked through a microscope and observed the surprising diversity of blood cells. In fact, the most common lab test, complete blood counts (CBC) guides healthcare in a wide range of uses from annual health screening, detection of disease, and monitoring of treatments. At Oneomics we are developing Next Generation CBC (NGC) a new single cell genomics technology to significantly expand on the standard CBC. Instead of only counting a few basic cell types, we use our single cell technology to report hundreds of distinct cell types and states. For the first time, we can begin to use the long known complexity and cellular diversity of the immune system for precision medicine.
-
Self Identified Competition
There are currently no competitors in this space This is an opportunity to update the most widely used clinical diagnostic test for the next century of personalised health.
-
Contact Applicant
Subscribe to our Administrator Dashboard to gain full access to this application. Learn More
